Progyny (NASDAQ:PGNY) Updates FY 2026 Earnings Guidance

Progyny (NASDAQ:PGNY) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 2.040-2.100 for the period, compared to the consensus earnings per share estimate of 1.860. The company issued revenue guidance of $1.4 billion-$1.4 billion, compared to the consensus revenue estimate of $1.4 billion. Progyny also updated its Q3 2026 guidance to 0.500-0.520 EPS.

Progyny Trading Down 3.7%

NASDAQ PGNY opened at $30.21 on Friday. The firm has a market capitalization of $2.37 billion, a P/E ratio of 39.23, a price-to-earnings-growth ratio of 2.49 and a beta of 1.01. The firm’s fifty day moving average price is $29.02 and its two-hundred day moving average price is $23.40. Progyny has a 1 year low of $16.10 and a 1 year high of $33.06.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.22. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The business had revenue of $350.51 million during the quarter, compared to the consensus estimate of $348.63 million. During the same period last year, the business posted $0.19 EPS. Progyny’s revenue was up 5.3% on a year-over-year basis. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, research analysts anticipate that Progyny will post 1.19 EPS for the current fiscal year.

Progyny declared that its Board of Directors has approved a share buyback plan on Tuesday, May 26th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 10.3% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on PGNY shares. Bank of America upped their price target on shares of Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Zacks Research upgraded shares of Progyny from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, July 8th. Leerink Partners set a $38.00 target price on Progyny in a research report on Wednesday, July 22nd. Truist Financial upped their price target on Progyny from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Finally, BTIG Research raised their price objective on Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Progyny has an average rating of “Moderate Buy” and an average target price of $33.25.

Insider Transactions at Progyny

In other news, COO Melissa B. Cummings sold 9,578 shares of Progyny stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $25.00, for a total transaction of $239,450.00. Following the completion of the transaction, the chief operating officer directly owned 73,371 shares in the company, valued at $1,834,275. This trade represents a 11.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Geoffrey Clapp sold 1,530 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $25.58, for a total value of $39,137.40. Following the completion of the transaction, the insider owned 59,117 shares in the company, valued at $1,512,212.86. This represents a 2.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 36,916 shares of company stock valued at $939,875. Corporate insiders own 9.90% of the company’s stock.

Key Stories Impacting Progyny

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported second-quarter adjusted earnings of $0.55 per share, above consensus estimates, while revenue reached $350.5 million, slightly exceeding expectations. EPS increased from $0.19 in the year-ago quarter, and revenue grew 5.3% year over year. Progyny, Inc. Announces Second Quarter 2026 Results
• Positive Sentiment: Management raised or reaffirmed an optimistic full-year profit outlook, guiding 2026 EPS to $2.04-$2.10 versus analyst expectations of $1.86. Full-year revenue guidance of approximately $1.4 billion was broadly in line with consensus. Progyny 2026 Q2 Results Earnings Call Presentation
• Neutral Sentiment: The earnings call and presentation provided additional detail on the quarterly performance and outlook, but the available reports do not indicate a material change to the company’s broader strategy. Progyny Q2 2026 Earnings Call Transcript
• Negative Sentiment: Third-quarter revenue guidance of $335 million-$345 million was below the roughly $350 million analyst consensus. Although the company’s Q3 EPS outlook of $0.50-$0.52 exceeded expectations, investors appear more concerned about the slower near-term top-line outlook, contributing to the negative reaction. Progyny Q2 Earnings and Revenues Beat Estimates

Institutional Trading of Progyny

A number of large investors have recently added to or reduced their stakes in PGNY. State Street Corp lifted its position in shares of Progyny by 1.5% during the 4th quarter. State Street Corp now owns 2,953,186 shares of the company’s stock valued at $75,838,000 after buying an additional 44,642 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Progyny by 260.9% during the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after purchasing an additional 1,621,688 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Progyny by 37.6% during the second quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after purchasing an additional 545,431 shares during the period. Geode Capital Management LLC increased its stake in shares of Progyny by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 1,972,219 shares of the company’s stock worth $50,655,000 after purchasing an additional 20,533 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Progyny by 12.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,712,039 shares of the company’s stock valued at $43,966,000 after buying an additional 184,679 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.